Emavusertib (CA-4948) is a drug which acts as a selective inhibitor of the enzyme Interleukin-1 receptor-associated kinase 4 (IRAK-4) and was developed for the treatment of some forms of cancer.[1][2][3]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H25N7O5 |
Molar mass | 491.508 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, et al. (December 2020). "Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies". ACS Medicinal Chemistry Letters. 11 (12): 2374–2381. doi:10.1021/acsmedchemlett.0c00255. PMC 7734642. PMID 33335659.
- ^ Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, et al. (May 2023). "Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases". Clinical Cancer Research. 29 (9): 1751–1762. doi:10.1158/1078-0432.CCR-22-1682. PMC 10150246. PMID 36749885.
- ^ Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW (2023). "IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies". Frontiers in Immunology. 14: 1239082. doi:10.3389/fimmu.2023.1239082. PMC 10637517. PMID 37954584.